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Chronic arsenic exposure is a major health 
concern in at least 70 countries, and an esti‑
mated 140 million people are exposed to lev‑
els of As in drinking water that exceed the 
World Health Organization standard of 10 
µg/L (Bagchi 2007; Kinniburgh et al. 2003; 
Smith et al. 2000). Chronic ingestion of As 
through drinking water is associated with 
cancers of the skin, liver, lung, and bladder 
(National Research Council 2001), isch‑
emic heart disease (Tseng et al. 2005), and 
neurologic consequences in both adults and 
children (Hansen et al. 2004; Wasserman 
et al. 2004). Premalignant skin lesions (i.e., 
melanosis, keratosis, and leukomelanosis) 
are hallmarks of chronic As ingestion by 
humans and, unlike internal cancers, which 
take decades to present, can develop within 
a few years of exposure (National Research 
Council 2001; Saha 2003). Previous stud‑
ies showed strong dose–response relation‑
ships between As exposure and skin lesions 
(Ahsan et al. 2006b; Guha Mazumder et al. 
1998). Because most As‑induced basal and 
squamous‑cell skin cancers develop from 
these premalignant lesions, skin lesions may 
be considered precursors of skin cancers 
(Ahsan et al. 2000). Although the mechanism 
by which As induces adverse health effects has 
not been clearly elucidated, multiple path‑
ways have been suggested, including oxida‑
tive‑dependent processes, inhibition of DNA 
repair, altered cellular proliferation, acquired 
apoptotic tolerance, and alterations in DNA 
methylation (Liu and Waalkes 2008).
Nutritional deficiencies are thought to 
confer increased risk for susceptibility to 
As‑induced skin lesions. Case–control studies 
using dietary questionnaires for nutritional 
assessment have found that undernourish‑
ment and low intake of folate, animal pro‑
tein, calcium, and fiber are associated with 
elevated risk for skin lesions and cancers 
(Hsueh et al. 1995; Mitra et al. 2004). 
Similarly, individuals who were < 80% of the 
standard body weight for their age and sex 
had a 1.6‑fold increase in the prevalence of 
keratosis (Guha Mazumder et al. 1998). In 
Pabna, Bangladesh, betel nut use increased 
and higher fruit and canned goods intake 
decreased the risk of As‑induced skin lesions 
(McCarty et al. 2006).
Folate plays an important role in one‑
carbon metabolism, the biochemical path‑
way that mediates the transfer of methyl 
groups from S‑adenosylmethionine (SAM) 
to numerous substrates, including As, DNA, 
and guanidinoacetate (GAA). The latter con‑
stitutes the final step in creatine biosynthesis 
and is a major consumer of SAM (Mudd and 
Poole 1975). Once ingested, inorganic As 
(InAs) may undergo one or two bio  meth‑
ylation reactions to generate monomethyl‑
arsonic acid (MMA) and dimethylarsinic acid 
(DMA), respectively. Studies from Taiwan 
have indicated that people with relatively 
lower proportions of DMA in urine have a 
higher risk of skin and bladder cancers (Chen 
et al. 2003a, 2003b) and peripheral vascular 
disease (Tseng et al. 2005). We previously 
reported a high prevalence of folate deficiency 
and hyperhomocysteinemia in a rural area 
within Araihazar, Bangladesh (Gamble et al. 
2005a); these factors were subsequently found 
to be associated with reduced As methylation 
(Gamble et al. 2005b). Furthermore, in a 
double‑blind placebo‑controlled folic acid 
supplementation trial, we reported that folic 
acid supplementation to participants with low 
plasma folate enhanced the methylation of As 
to DMA and increased urinary As excretion 
(Gamble et al. 2006). Moreover, this inter‑
vention significantly lowered the concentra‑
tions of As in blood, primarily by lowering 
blood MMA (Gamble et al. 2007). This latter 
finding is particularly important in light of 
landmark work by Styblo et al. (2000) and 
Petrick and colleagues (Drobna et al. 2005; 
Petrick et al. 2000, 2001) indicating that 
MMA(III) is the most toxic metabolite, both 
in vitro and in vivo.
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Ba c k g r o u n d: Arsenic methylation relies on folate-dependent one-carbon metabolism and facilitates 
urinary As elimination. Clinical manifestations of As toxicity vary considerably among individuals 
and populations, and poor methylation capacity is thought to confer greater susceptibility.
oB j e c t i v e: After determining that folate deficiency, hyperhomocysteinemia, and low urinary 
creatinine are associated with reduced As methylation, and that As exposure is associated with 
increased genomic methylation of leukocyte DNA, we asked whether these factors are associated with 
As-induced skin lesion risk among Bangladeshi adults.
Me t h o d s : We conducted a nested case–control study of 274 cases who developed lesions 2 years 
after recruitment, and 274 controls matched to cases for sex, age, and water As.
re s u l t s: The odds ratios and 95% confidence intervals (CIs) for development of skin lesions 
for participants who had low folate (< 9 nmol/L), hyperhomocysteinemia (men, > 11.4 µmol/L; 
women, > 10.4 µmol/L), or hypomethylated leukocyte DNA at recruitment (< median) were 
1.8 (95% CI, 1.1–2.9), 1.7 (95% CI, 1.1–2.6), and 1.8 (95% CI, 1.2–2.8), respectively. Compared 
with the subjects in the first quartile, those in the third and fourth quartiles for urinary creatinine 
had a 0.4-fold decrease in the odds of skin lesions (p < 0.01).
co n c l u s i o n s: These results suggest that folate deficiency, hyperhomocysteinemia, and low   urinary 
creatinine, each associated with decreased As methylation, are risk factors for As-induced skin 
lesions. The increased DNA methylation associated with As exposure previously observed, and 
confirmed among controls in this study, may be an adaptive change because hypomethylation of 
leukocyte DNA is associated with increased risk for skin lesions.
key w o r d s : arsenic, Bangladesh, DNA methylation, epigenetics, folate, folate deficiency, global 
methyla  tion, homocysteine, hyperhomocysteinemia, skin lesions. Environ Health Perspect 117:254–260 
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Other macromolecules, such as DNA, also 
undergo methylation reactions that depend 
on one‑carbon metabolism. DNA methyla‑
tion has several important functions in mam‑
mals, including regulation of gene expression, 
preservation of chromosomal integrity, paren‑
tal imprinting, and X‑chromosome inactiva‑
tion (Hermann et al. 2004). Two patterns 
of DNA methylation are found to be altered 
in nearly all forms of cancer. First, aber‑
rant increases in methylation of CpG‑rich 
islands located within promoter regions—
that is, gene‑specific hypermethylation—is 
associated with transcriptional repression; 
this can silence genes that otherwise function 
to prevent tumor growth and development. 
Second, a relative reduction in the overall 
level of methylation of non‑CpG‑island cyto‑
sines distributed throughout the genome (i.e., 
genomic DNA hypomethylation) is associated 
with reactivation of cellular proto‑  oncogenes 
and can lead to chromosomal instability 
(Robertson and Wolffe 2000). Exposure to 
As (Chen et al. 2004; Zhao et al. 1997) and 
folate deficiency (Davis and Uthus 2004; 
Shelnutt et al. 2004) have both been asso‑
ciated with alterations in DNA methyla‑
tion, and these and other epigenetic marks 
(Ramirez et al. 2008; Zhou et al. 2008) have 
been proposed as mediators of As‑induced 
carcinogenesis (Mass and Wang 1997; Pilsner 
et al. 2007).
We therefore hypothesized that genomic 
DNA methylation and/or key regulators of 
one‑carbon metabolism would influence risk 
for As‑induced skin lesions. We report here 
the results of a nested case–control study of 
As‑exposed Bangladeshi adults that prospec‑
tively assessed the associations between plasma 
folate, B12, and homocysteine; urinary creati‑
nine; and genomic methylation of peripheral 
blood leukocyte (PBL) DNA and the risk for 
subsequent development of As‑induced pre‑
malignant skin lesions.
Materials and Methods
The present study derives its participants from 
a large parent cohort study, the Health Effects 
of Arsenic Longitudinal Study (HEALS), 
which is an ongoing prospective cohort 
study in Araihazar, Bangladesh. Our data 
on socioeconomic status indicate that this 
region is not particularly poor by Bangladesh 
standards (Center for International Earth 
Science Information Network 2007). The 
HEALS cohort study includes > 12,000 
men and women between 18 and 65 years 
of age recruited beginning in October 2000, 
and whom we continue to follow at 2‑year 
intervals. At baseline and at 2‑year follow‑up 
visits, a comprehensive clinical examination 
is conducted by physicians trained to diag‑
nose arsenicosis skin lesions. Further details 
on clinical examinations have been reported 
elsewhere (Ahsan et al. 2006a; Chen et al. 
2007). Skin lesions include melanosis, leuko‑
melanosis, and keratosis. Melanosis is charac‑
terized by the hyperpigmentation of the skin 
over wide body surface areas. Leukomelanosis 
is characterized by both hyperpigmentation 
and hypopigmentation of the skin over wide 
body surface areas. Keratosis is character‑
ized by bilateral thickening of the skin of the 
palms and soles (Ahsan et al. 2006b).
Oral informed consent was obtained by 
our Bangladeshi field staff physicians, who 
read an approved assent form to the study 
participants. This study was approved by the 
Institutional Review Boards of Columbia 
University  Medical  Center  and  the 
Bangladesh Medical Research Council.
Selection of cases and controls. Of the 
11,746 participants recruited by May 2002, 
9,727 participants completed the baseline 
physical examination, provided both urine 
and blood samples, and were free of skin 
lesions; we identified 712 prevalent cases of 
skin lesions and excluded them from the pres‑
ent study (Chen et al. 2007) to ensure that 
exposure assessment preceded disease onset. 
The present analysis includes 274 incident skin 
lesion cases that were diagnosed at the first 
2‑year follow‑up between November 2002 and 
April 2004. We individually matched an equal 
number of controls to cases for sex and age 
(within 5 years) and frequency matched them 
for water As (± 100 µg/L). Of the 274 skin 
lesion cases, 201 had melanosis, 11 had kera‑
tosis, 3 had leukomelanosis, and the remaining 
59 had both keratosis and melanosis. Plasma 
samples were unavailable for 25 cases; we ana‑
lyzed folate and B12 for the remaining 248 
pairs. Furthermore, an adequate volume of 
whole blood was available for blood As analy‑
ses only for a subset of 193 pairs.
Analytic techniques. Sample collection 
and handling. At the baseline recruitment 
visit, we collected whole venous blood samples 
into Vacutainer tubes containing serum sepa‑
rators and into EDTA tubes. We collected 
spot urine samples in 50‑mL acid‑washed 
tubes and placed both blood and urine sam‑
ples into portable coolers immediately after 
collection. Within 2–8 hr, we centrifuged 
the serum separation tubes at 3,000 × g for 
10 min at 4°C, to separate serum from cells in 
our laboratory located in Dhaka. We stored 
all samples in Dhaka in a –20°C freezer and 
then shipped them in a frozen state on dry 
ice to Columbia University for analysis. At 
Columbia, whole blood and urine samples 
were stored at –20°C. Serum samples were 
stored at –80°C.
Water As. Water As concentrations of 
tube wells at each participant’s home were 
obtained during a survey of all wells in the 
study region carried out between January 
and May 2000 (Van Geen et al. 2003). We 
analyzed samples at Columbia University’s 
Lamont Doherty Earth Observatory by graph‑
ite furnace atomic absorption (GFAA) with 
a Hitachi Z‑8200 system (Hitachi, Tokyo, 
Japan), which has a detection limit of 5 µg/L. 
Those samples found to have nondetectable 
As by GFAA we subsequently analyzed by an 
Axiom Single Collector high‑resolution induc‑
tively coupled mass spectrometry (ICP‑MS; 
Thermo Elemental, Erlangen, Germany), 
which has a detection limit of 0.1 µg/L 
(Cheng et al. 2004).
Total urinary As. We measured total uri‑
nary As concentrations by GFAA spectrom‑
etry in a graphite furnace system (AAnalyst 
600; PerkinElmer, Shelton, CT) in the 
Columbia University Trace Metals Core Lab, 
as described previously (Nixon et al. 1991). 
Our laboratory participates in a quality con‑
trol program for total urinary As coordinated 
by Philippe Weber at the Quebec Toxicology 
Center (Quebec, Canada). During the course 
of this study, intraclass correlation coefficients 
between our laboratory’s values and samples 
calibrated at Weber’s laboratory were 0.99, 
whereas the within‑ and between‑day coef‑
ficients of variation (CVs) were 3% and 12%, 
respectively. We analyzed urinary creatinine 
using a method based on the Jaffe reaction 
(Slot 1965) and used it to correct for differ‑
ences in urine concentration.
Whole blood As and As metabolites. We 
recently demonstrated that blood As is an 
excellent biomarker of exposure in Bangladesh 
(Hall et al. 2007). In a similar fashion, whole‑
blood specimens were digested according to 
method of Csanaky and Gregus (2003). We 
thawed frozen samples and mixed them with 
0.1 vol 5.5% Triton X‑100. After the addition 
of 0.1 vol 150 mM aqueous mercury chlo‑
ride and incubation on ice for 1 min, samples 
were deproteinized with 1 vol 0.66 M ice‑cold 
HClO4 and centrifuged for 10 min at 4,000 
rpm. The supernatant was mixed with mobile 
phase, injected onto the high‑performance 
liquid chromatography (HPLC) column, and 
detected by ICP‑MS with dynamic reaction 
cell (DRC; PerkinElmer). We similarly pro‑
cessed calibration standards of a mixture of 
As metabolites. ICP‑MS‑DRC (PerkinElmer) 
coupled to HPLC separates and detects six As 
metabolites chromatographically separated by 
anion exchange using a PRP‑X100 column 
(Hamilton, Reno, NV). The mobile phase was 
10 mM ammonium nitrate/ammonium phos‑
phate, pH 9.1. Arsenocholine (AsC), arseno‑
betaine, MMA, DMA, As(III), and As(V) are 
detectable with precision in blood samples 
with total As concentrations as low as 3 µg/L. 
We report InAs as total InAs because As(III) 
can oxidize to As(V) during sample transport 
and preparation. However, most of the InAs 
in blood appeared as As(III). We used two 
types of quality control samples. We purchased Pilsner et al.
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blood samples from the Institut de Sante 
Publique du Quebec that have known con‑
centrations of 23 different elements, including 
As. We also have our own set of blood samples 
spiked with all five metabolites, AsC, As(III), 
DMA, MMA, As(V), at three different levels 
to cover the expected range of As in unspiked 
samples. We ran both sets of quality control 
samples in the beginning of every working 
day and after every 10 samples throughout 
the day. The average within‑ and between‑day 
CVs for all metabolites were 2.9% and 5.7%, 
respectively, and those for whole‑blood As 
were 4.1% and 6.6%, respectively.
Isolation of PBL DNA. We isolated 
DNA from frozen whole‑blood samples using 
FlexiGene DNA kits (Qiagen, Valencia, CA) 
following the manufacturer’s protocol, except 
that we added an additional centrifugation 
step at 10,000 × g for 5 min immediately after 
protease digestion to pellet any remaining 
proteins or lipids, and then transferred the 
subsequent supernatant into a new micro‑
centrifuge tube containing 150 µL of isopro‑
panol. We then isolated DNA according to 
manufacture’s protocol.
Genomic DNA methylation. We deter‑
mined genomic DNA methylation by the 
methyl acceptance assay using the method 
of Balaghi and Wagner (1993). We incu‑
bated DNA with [3H]‑SAM in the presence 
of SssI methylase, a prokaryotic CpG‑specific 
methylase enzyme from Spiroplasma, which 
indiscriminately methylates all unmethylated 
cytosines in CpG sequences. Therefore, the 
ability of DNA to incorporate [3H]methyl 
groups in vitro is inversely related to endog‑
enous DNA methylation. Briefly, we incu‑
bated 250 ng of DNA with 3 U SssI methylase 
(New England Biolabs, Beverly, MA), 3.8 µM 
(1.1 µCi) 3H‑labeled SAM (GE Healthcare, 
Piscataway, NJ), and EDTA, dithiothre‑
itol, and Tris‑HCl (pH 8.2), which we 
then incubated for 1 hr at 37°C. The reac‑
tion was terminated on ice and 15 µL of the 
reaction mixture was applied onto Whatman 
DE81 filter paper (Fisher, Pittsburgh, PA). 
We washed the filter on a vacuum filtra‑
tion apparatus three times with 5 mL 0.5 M 
sodium phosphate buffer (pH 8.0), followed 
by 2 mL each of 70% and 100% ethanol. 
We placed dried filters each in a vial with 
5 mL scintillation fluid (Scintisafe; Fisher) 
and analyzed them by a Tri‑Carb 2100TR 
Liquid Scintillation Analyzer (PerkinElmer). 
We processed each DNA sample in duplicate, 
and each processing run included samples for 
background (reaction mixture with all com‑
ponents except SssI enzyme), a hypomethyla‑
tion control (HeLa cell DNA), and a quality 
control sample (DNA extracted from a whole‑
blood sample). The intraassay and interassay 
CVs were 1.8% and 5.3%, respectively. To 
quantify the amount of double‑stranded DNA 
(dsDNA) in each reaction, we used an ali‑
quot of the assayed DNA to determine DNA 
concentrations using PicoGreen dsDNA 
Quantitation Reagent (Invitrogen, Carlsbad, 
CA). We expressed all disintegrations per min‑
ute (dpm) per   microgram of DNA.
Plasma folate and B12. We analyzed 
plasma folate and total cobalamin by radio‑
immunoassay (Quantaphase II; Bio‑Rad 
Laboratories, Richmond, CA) as previously 
reported (Gamble et al. 2005a). The within‑ 
and between‑day CVs for folate were 3% and 
12%, respectively, and those for cobalamin 
were 3% and 12%, respectively.
Plasma total homocysteine concentra-
tions. We measured plasma total homo‑
cysteine concentrations by HPLC with 
fluorescence detection according to the 
method described by Pfeiffer et al. (1999), 
and as previously reported (Gamble et al. 
2005a, 2005b). The within‑ and between‑
day CVs for total homocysteine were 3% and 
12%, respectively.
Statistical analysis. We calculated descrip‑
tive statistics for characteristics of the study 
sample separately for cases and controls. We 
tested differences in matched case and con‑
trol pairs using McNemar’s test for binary 
variables, Bowker’s test for categorical vari‑
ables, and signed rank test for quantitative 
variables. We used conditional logistic regres‑
sion analysis to estimate odds ratios (ORs) 
and 95% confidence intervals (CIs) for the 
effect of predictors on the development of 
skin lesions, with and without control for 
Table 1. Demographic and clinical data of subjects in the current study (274 pairs).
  Controls (n = 274)  Cases (n = 274)  Difference in matched pairs
Variable  Value  Median (interquartile range)  Value  Median (interquartile range)  (p-value)
Male   70.4 (193)    70.4 (193)    1.0
Smoked cigarettes  58.4 (160)    60.6 (166)    0.48
Use of betel nut (272 pairs)  48.9 (133)    58.1 (158)    0.02
House type          0.36
  Thatched/other  11.0 (30)    9.1 (25)   
  Corrugate  70.4 (193)    75.2 (206)   
  Semi/pakka  18.6 (51)    15.7 (43)   
Education (years)          0.06
  None  44.2 (121)    50.7 (139)   
  1–5  27.0 (74)    28.1 (77)   
  > 5  28.8 (79)    21.2 (58)   
Age (years)  44.1 ± 9.6  45 (37–51)  44.7 ± 9.7  45 (38–52)  < 0.0001
BMI (270 pairs)  19.6 ± 3.1  19.4 (17.4–21.4)  19.4 ± 2.9  18.8 (17.4–21.2)  0.39
Water As (µg/L)  142.9 ± 140.1  114 (26–208)  148 ± 140  117 (41–205)  0.02
Urinary As (µg/L)  159.8 ± 157.9  113 (55–205)  171 ± 160  121 (61–236)  0.49
Urinary As/Cr (µg/g cr)  265.5 ± 213.6  203 (116–350)  355 ± 351  261 (137–464)  < 0.0001
Urinary creatinine(mg/dl)  70.6 ± 49.1  57.3 (32.2–98.1)  62.7 ± 52.8  47.1 (27.1–84.3)  0.02
Detectable blood As (µg/L) 196 pairs  11.0 ± 6.7  9.6 (6.5–14.2)  14.3 ± 10.0  11.8 (7.3–17.6)  < 0.0001
Percent blood As nondetectable   28.5 (78)    4.7 (13)    < 0.0001
Plasma folate (nmol/L) 233 pairs  9.0 ± 5.0  7.6 (5.6–11.3)  8.6 ± 5.3  7.2 (5.3–10.2)  0.10
Plasma folate < 9 nmol/L   58.4 (136)    69.5 (162)    0.009
Plasma B12 (pmo/L) 230 pairs  254.7 ± 140.4  222 (158–320)  250 ± 141  216 (143–308)  0.92
Plasma B12 < 151 pmo/L   23.0 (53)    28.3 (65)    0.16
Plasma homocysteine(µmo/L)  12.9 ± 7.7  10.9 (8.6–14.4)  13.8 ± 10.0  11.6 (9.0–15.0)  0.03
Hyperhomocysteinemiaa   46.0 (126)    56.2 (154)    0.008
Plasma selenium (µg/L) 196 pairs  152.8 ± 25.4  150 (135–168)  148 ± 21.2  149 (133–165)  0.13
Genomic methylation of PBL DNA  59,408 ± 8,041  58,666 (54,825–62,846)  59,648 ± 8,548  59,536 (55,688–62,814)  0.58
  (DPM /µg DNA)         
Values are % (no.) or mean ± SD. p-Values were calculated based on tests for difference in matched pairs: McNemar’s test for binary variables, Bowker’s test for categorical variables 
and signed rank test for quantitative variables.
aDefined as ≥ 10.4 µmol/L for women and ≥ 11.4 µmol/L for men. Arsenic-induced skin lesions and one-carbon metabolism
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potential confounders. The main predic‑
tors included indicators for low folate (< 9 
nmol/L), hyperhomocysteinemia (men, 
> 11.4 µmol/L; women, > 10.4 µmol/L), and 
genomic DNA hypomethylation (less than 
the median of 58,934 dpm/µg DNA). We log 
transformed variables with skewed distribu‑
tions such as blood As, water As, urinary As, 
and urinary creatinine to reduce the impact 
of extreme values in the analysis. For those 
variables subjected to log transformation, the 
ORs of developing skin lesions are for the 
doubling of exposure levels. We conducted all 
the analyses using SAS software, version 9.1.3 
(SAS Institute Inc., Cary, NC).
Results
Table 1 presents the characteristics of the 
study population. We found no significant 
differences in baseline body mass index (BMI) 
or sociodemographic variables such as house 
type and education between matched skin 
lesion case and control pairs. Although loosely 
matched on age (± 5 years) and well water As 
(± 100 µg/L), controls were younger and had 
lower water As levels than cases (p < 0.0001 
and 0.02, respectively). Cases were more 
likely to report betel nut use than were con‑
trols (p = 0.02) and had higher concentra‑
tions of blood As (p < 0.0001) and urinary As 
adjusted for creatinine (p < 0.0001); however, 
in the latter case, this difference was driven in 
part by significantly higher concentrations of 
urinary creatinine in the controls (p = 0.02). 
Unadjusted urinary As concentrations did not 
significantly differ between cases and controls. 
Although there was no significant difference 
in mean plasma folate concentrations between 
cases and controls, using published reference 
values for plasma folate (Christenson et al. 
1985), 69.5% of cases versus 58.4% of con‑
trols had low plasma folate (< 9 nmol/L; p = 
0.009). Furthermore, plasma homocysteine 
concentrations were higher in cases than 
controls (p = 0.03). With sex‑specific cut‑
offs derived from the Third National Health 
and Nutrition Examination Survey (Selhub 
et al. 1999), cases had a higher prevalence of 
hyperhomocysteinemia (men, ≥ 11.4 µmol/L; 
women, > 10.4 µmol/L) than did controls 
(56.2% vs. 46.0%, respectively; p = 0.009). 
Mean genomic methylation of PBL DNA 
did not differ between cases and controls. 
Demographic and clinical data did not dif‑
fer between the 274 pairs and the subsets of 
233 and 193 pairs that we used for plasma 
folate and blood As analyses, respectively (data 
not shown).
Table 2 provides the unadjusted and 
adjusted ORs for skin lesions derived from 
conditional logistic regression analysis. Using 
sex‑specific cutoffs for hyperhomocysteinemia, 
individuals with hyperhomocysteinemia were 
1.7 (95% CI, 1.1–2.6) times more likely to 
have skin lesions compared with those with‑
out hyperhomocysteinemia after controlling 
for age, urinary As and creatinine, and betel 
nut use. The subset of 233 pairs with plasma 
folate and B12 concentrations had an esti‑
mated OR of 1.8 (95% CI, 1.1–2.9) for skin 
lesions comparing individuals with and with‑
out low folate nutritional status (< 9 µmol/L). 
B12 deficiency was not associated with the 
odds of skin lesions. Betel nut use conferred 
a modest 1.5‑fold (95% CI, 1.0–2.2) increase 
in the odds in skin lesion development com‑
pared with those who did not use betel nut, 
after adjusting for covariates.
The interaction between hyperhomo‑
cysteinemia and folate status, although not 
statistically significant, suggested a possible 
joint effect of these variables (p = 0.08). To 
aid in interpretation, we stratified individuals 
into four groups to determine the combined 
effect of hyperhomocysteinemia and/or low 
folate on skin lesion development. Compared 
with the reference group (low homocysteine 
and high folate), individuals who had normal 
homocysteine but low folate or high folate 
and hyperhomocysteinemia had an OR of 2.0 
(95% CI, 1.1–3.5) and 2.4 (95% CI, 1.1–5.4) 
for skin lesions, respectively. Moreover, indi‑
viduals with both hyperhomocysteinemia and 
low folate at the time of enrollment had a simi‑
lar OR, 2.3 (95% CI, 1.3–3.9) for skin lesions.
Individuals with hypomethylation of 
PBL DNA (i.e., dpm per microgram DNA 
> median) were 1.8 (95% CI, 1.2–2.8) times 
more likely to have skin lesions after adjust‑
ing for age, urinary As and creatinine, and 
betel nut use. Using tertiles of DNA methyla‑
tion, the estimated ORs for individuals in 
the second and third tertiles of [3H]‑methyl 
incorporation (higher dpm values, i.e., lower 
PBL DNA methylation) compared with the 
lowest tertile were 1.6 (95% CI, 1.0–2.5) and 
1.5 (95% CI, 0.9–2.5) for skin lesion risk 
after adjusting for covariates (Table 2).
Finally, for every doubling of urinary crea‑
tinine concentrations (range, 5–376 mg/dL), 
the estimated adjusted OR for skin lesions was 
0.7 (95% CI, 0.5–0.8). Further analyses using 
quartiles of urinary creatinine showed that, 
compared with the first quartile, individuals in 
the third and fourth quartile for urinary creati‑
nine had an estimated adjusted OR of 0.4 for 
skin lesion development (p < 0.01) (Table 2).
Consistent with our previous study (Pilsner 
et al. 2007), in controls we observed nega‑
tive correlations between dpm per microgram 
PBL DNA and various markers of As exposure 
including urinary As, urinary As per gram cre‑
atinine, and blood As (Spearman coefficients: 
–0.12, p = 0.04; –0.11, p = 0.07; and –0.19 
p = 0.007, respectively), suggesting that As 
exposure is associated with increased genomic 
methylation of PBL DNA. After stratifying 
by folate nutritional status (< 9 nmol/L vs. 
≥ 9 nmol/L) the negative association between 
blood As and dpm per microgram PBL DNA 
among controls was significant only in indi‑
viduals with adequate folate nutritional status 
(Spearman correlation coefficient: ≥ 9 nmol/L, 
–0.26, p = 0.02, vs. < 9 nmol/L, –0.15, p = 
0.09). These data support our previous find‑
ings indicating that As exposure is positively 
associated with genomic methylation of 
PBL DNA and, furthermore, that this asso‑
ciation is modified by folate nutritional status 
(Pilsner et al. 2007). We found no associations 
Table 2. ORs (95% CIs) for predictors of skin lesions, derived from logistic models with and without control 
for other factors.
  Unadjusted OR (95% CI)  Adjusted OR (95% CI)
Predictor  (n = 274 pairs)  (n = 272 pairs)
Low B12 (B12 < 151 pmol/L)a  1.4 (0.9–2.2)  1.5 (0.9–1.6)b
Low folate (folate < 9 µmol/L)c  1.7 (1.1–2.6)**  1.8 (1.1–2.9)b,*
Hyperhomocysterinemia  1.7 (1.1–2.4)**  1.7 (1.1–2.6)b,*
Folate and homocysteinemia combinedc   
  Low homocysteine/high folate  1.0  1.0d
  Low homocysteine/low folate   1.7 (1.0–2.9)*  2.0 (1.1–3.5)*
  High homocysteine/high folate  1.7 (0.8–3.4)  2.4 (1.1–5.4)*
  High homocysteine/low folate  2.0 (1.2–3.3)**  2.3 (1.3–3.9)**
DNA hypomethylation (DPM > median)  1.7 (1.1–2.5)*  1.8 (1.2–2.8)b,**
DNA methylation by tertiles (DPM/µg DNA)   
  1st tertile (30,318–56,459)  1.00  1.00b
  2nd tertile (56,460–61,689)  1.6 (1.0–2.4)*  1.6 (1.0–2.6)*
  3rd tertile (61,690–95,734)   1.4 (0.9–2.3)  1.5 (0.9–2.5)
Urinary creatinine (fold increase)  0.8 (0.7–1.0)*  0.7 (0.5–0.8)c,#
Urinary creatinine by quartiles   
  4.5–29  1.00  1.00d
  29.1–52.3  1.0 (0.6–1.7)  0.7 (0.4–1.3)
  52.4–89.9  0.7 (0.4–1.1)  0.4 (0.2–0.8)**
  90.0–376  0.6 (0.4–1.0)*  0.4 (0.2–0.7)**
Betel nut use  1.5 (1.1–2.2)*  1.5 (1.0–2.2)e,*
aExcluding 44 pairs with unknown plasma B12. bExcluding 41 pairs with unknown plasma folate. cControlled for age, uri-
nary As and creatinine, and betel nut use. dControlled for age, urinary As, and betel nut use. eControlled for age, urinary 
As, and urinary creatinine.
*p ≤ 0.05; **p < 0.01; #p < 0.001.Pilsner et al.
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between As exposure and methylation of PBL 
DNA methylation among cases.
Table 3 provides the full conditional 
regression model with all predictors included 
simultaneously. In the full model, we found 
that all individual predictors of skin lesion 
development remained significant except betel 
nut use, which dropped out of the model. 
Urinary creatinine was a significant predic‑
tor of future development of skin lesions: 
For every doubling of urinary creatinine, the 
risk of skin lesions was reduced by 60% (p = 
0.0001). Taken together, this suggests that 
genomic hypomethylation of PBL DNA, 
hyperhomocysteinemia, low folate, age, and 
urinary As are all risk factors for the subse‑
quent development of skin lesions.
Discussion
The objectives of this study were to evaluate 
whether genomic methylation of PBL DNA 
and/or factors that influence As methylation—
folate nutritional status, hyperhomocysteine‑
mia, or urinary creatinine—influence the risk 
for subsequent development of As‑induced 
skin lesions. Previous nutritional studies 
investigating As‑induced skin lesions have 
relied on dietary questionnaires or have mea‑
sured blood nutrient concentrations in sam‑
ples drawn from prevalent skin lesion cases 
(Chung et al. 2006; McCarty et al. 2006; 
Mitra et al. 2004). To our knowledge, this 
is the first prospective study to investigate 
associations between plasma concentrations 
of folate and homocysteine and genomic PBL 
DNA methylation levels and development of 
As‑induced skin lesions.
One-carbon metabolism, folate and homo-
cysteine, and As methylation and toxicity. 
One‑carbon metabolism facilitates the transfer 
of one‑carbon units that are ultimately used 
either for nucleotide biosynthesis or for the 
methylation of a variety of substrates, includ‑
ing DNA, As, and GAA. All methylation reac‑
tions generate the methylated product and 
S‑adenosylhomocysteine (SAH). Hydrolysis of 
SAH generates homocysteine and adenosine; 
this reaction is reversible with equilibrium 
dynamics that favor SAH synthesis rather than 
hydrolysis. Removal of SAH can be achieved 
by downstream remethylation of homocysteine 
using methyl groups donated by 5‑methyl tet‑
rahydrofolate or betaine. In folate deficiency, 
concentrations of homocysteine, and conse‑
quently SAH, are elevated (Yi et al. 2000). 
Because SAH is a potent product inhibitor of 
most methyltransferase enzymes, including 
DNA methyltransferases (Cox et al. 1977) and 
As methyltransferase (De Kimpe et al. 1999), 
its efficient removal is critical for maintaining 
transmethylation reactions.
Population‑based studies in Taiwan 
have indicated that individuals whose urine 
contains lower proportions of DMA and 
higher proportions of MMA are at a higher 
risk for skin lesions (Ahsan et al. 2007), skin 
and bladder cancers (Chen et al. 2003a, 
2003b), and peripheral vascular disease 
(Tseng et al. 2005). Thus, factors that influ‑
ence As methyla  tion may influence risk for 
As‑induced disease. We previously found sig‑
nificant associations between homocysteine 
and/or folate nutritional status and As methy‑
lation (Gamble et al. 2005b). In addition, in 
a randomized trial in Bangladeshi adults, folic 
acid supplementation to participants with 
low plasma folate enhanced As methylation 
and lowered blood As compared with pla‑
cebo (Gamble et al. 2006, 2007), because 
of the shorter circulating half‑life of DMA 
compared with other As species. Our find‑
ings suggest that both folate deficiency and 
hyperhomocysteinemia are risk factors for 
the development of skin lesions. Moreover, 
hyperhomocysteinemia, low plasma folate, 
or the combination of both each conferred 
a similar 2‑fold increase in risk. We propose 
that this risk is attributable to the reduced 
capacity to methylate As. Although B12 is an 
essential cofactor for methionine synthase, 
the enzyme that catalyzes the remethylation 
of homocysteine to methionine, we found no 
increase risk for skin lesions among individu‑
als with low B12 concentrations. Finally, betel 
nut use generates reactive oxygen species (Nair 
et al. 2004), which could affect folate levels 
through oxidative degradation. We previously 
found betel nut use to be negatively associ‑
ated with plasma folate (Gamble et al. 2005a; 
Pilsner et al. 2007), so it is not surprising that 
betel nut use did not add to the model once 
we included folate status.
As and genomic PBL DNA methyla-
tion. Genomic DNA hypomethylation com‑
monly occurs in tumors and transformed cells 
and is thought to constitute an early event 
in some cancers (Robertson and Wolffe 
2000). Genomic methylation of PBL DNA 
is reported to be positively associated with 
plasma folate concentrations (Pilsner et al. 
2007; Shelnutt et al. 2004) and negatively 
associated with plasma homocysteine and 
SAH concentrations (Ingrosso et al. 2003; 
Yi et al. 2000). Among individuals with 
As‑induced skin lesions, gene‑specific pro‑
moter DNA hypermethylation of p53 and 
p16 in PBL DNA has recently been reported 
(Chanda et al. 2006). Previous animal stud‑
ies have suggested that As induces hepatic 
genomic hypomethylation of DNA (Chen 
et al. 2004; Zhao et al. 1997).
Although PBLs are not known targets of 
As, As is an effective therapeutic agent in the 
treatment of acute promyelocytic leukemia, 
indicating that As distributes to PBL pro‑
genitor cells and influences their cellular func‑
tion. Also, approximately 62% of PBLs are 
neutrophils that are relatively short‑lived (< 1 
week). Because these cells are rapidly dividing, 
they may respond more quickly to factors that 
influence DNA methylation than do cells that 
turn over more slowly.
In the present study, we found that indi‑
viduals with genomic hypomethylation of 
PBL DNA had a 1.8‑fold increase risk for skin 
lesions, suggesting that changes in genomic 
methylation of PBL DNA may serve as an 
early biomarker of molecular events associ‑
ated with the initiation and/or progression of 
As‑induced skin lesions. In a previous study of 
apparently healthy adults, we found As expo‑
sure to be positively associated with genomic 
methylation of PBL DNA, and that folate 
nutritional status modified this effect (Pilsner 
et al. 2007). The present study confirms both 
of these findings among controls, whereas we 
found no significant associations among skin 
lesion cases. We speculate that adequate folate 
may be permissive for an adaptive increase in 
genomic methylation of PBL DNA associ‑
ated with As exposure, and that individu‑
als who are similarly exposed but in whom 
the increase in genomic DNA methylation 
does not occur (or cannot be sustained) are at 
elevated risk for skin lesions.
The underlying mechanisms and physi‑
ologic consequences of As‑induced alterations 
in genomic DNA methylation are unknown. 
As(III) (5 µM) exposure for 29 weeks has 
resulted in genomic DNA hypomethylation 
in human prostatic epithelial cells, which 
was accompanied by reduced DNA methyl‑
transferase activity (Benbrahim‑Tallaa et al. 
2005). Chronic As exposure was also shown 
to cause hypermethylation of p16INK4a and 
RASSF1A promoter regions in mouse lung 
tissue, implicating epigenetic alterations in 
tumor suppressor genes in As‑induced lung 
carcinogenesis (Cui et al. 2006). Moreover, 
in utero As exposure was reported to induce a 
loss of methyl groups in CpG‑rich regions in 
newborn mouse liver (Xie et al. 2007).
Urinary creatinine and risk for As-induced 
premalignant skin lesions. Numerous studies 
have shown that urinary creatinine is a strong 
Table 3. Adjusted ORs derived from logistic model 
for all predictors of skin lesions (n = 231 case–
control pairs).
Variable  OR (95% CI) 
DNA methylation
  1st tertile  1
  2nd tertile  2.2 (1.3–3.8)**
  3rd tertile   1.8 (1.0–3.2)*
Low homocysteine/high folate  1
Low homocysteine/low folate  2.4 (1.3–4.5)**
High homocysteine/high folate  2.7 (1.1–6.3)*
High homocysteine/low folate  2.8 (1.5–5.2)#
Urinary creatinine (fold increase)  0.6 (0.4–0.7)#
Urinary As (fold increase)  1.4 (1.0–1.6)**
Age  1.3 (1.1–1.5)**
Betel nut use   1.3 (0.8–2.1) 
*p < 0.05; **p < 0.01; #p < 0.001.Arsenic-induced skin lesions and one-carbon metabolism
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predictor of As methylation (Ahsan et al. 2007; 
Gamble et al. 2005b, 2006; Hall et al. 2007). 
The present study provided an opportunity to 
test the clinical relevance of this serendipitous 
finding. Remarkably, higher urinary creatinine 
concentrations were associated with a reduced 
risk for skin lesions; every doubling of urinary 
creatinine concentrations was associated with 
a roughly 60% reduced risk for skin lesions 
development.
GAA is formed in a reaction catalyzed by 
l‑arginine:glycine amidinotransferase (AGAT). 
GAA is then methylated by GAA methyltrans‑
ferase to generate creatine. Increases in plasma 
creatine concentrations, whether derived from 
de novo biosynthesis or exogenous sources such 
as protein in the diet, down‑regulate endog‑
enous creatine biosynthesis by pretranslational 
repression of AGAT expression. Creatine is 
nonenzymatically degraded to creatinine, which 
is excreted in urine at a relatively constant rate, 
so it is commonly used to adjust urinary As 
and many other metabolites for fluctuations in 
hydration. However, recent papers have high‑
lighted the potential for introducing bias or 
confounding due to the influence of age, sex, 
and muscle mass on urinary creatinine (Barr 
et al. 2005; Gamble and Liu 2005). The present 
finding adds another dimension to this issue. 
Why urinary creatinine is so robustly associated 
with As methylation, and here with risk for skin 
lesions, is completely unknown. One possibil‑
ity is that the down‑regulation of endogenous 
creatine biosynthesis in response to ingestion 
of dietary creatine may spare methyl groups 
and thereby facilitate other transmethylation 
reactions, such as As methylation. However, 
additional studies will be required to elucidate 
the mechanism underlying these findings.
In conclusion, our results suggest that fac‑
tors that influence folate‑dependent one‑carbon 
metabolism play important roles in the risk for 
future development of As‑induced skin lesions, 
presumably due to their influence on As 
methylation. We found that folate deficiency, 
hyperhomocysteinemia, and genomic hypom‑
ethylation of PBL DNA are all independent 
risk factors for skin lesions. The novel finding 
of the protective role of urinary creatinine in 
the development of skin lesions warrants fur‑
ther investigations; we speculate this may be 
related to the role of one‑carbon metabolism 
in creatine biosynthesis. We have confirmed 
that As exposure is associated with increased 
DNA methylation and that this effect is modi‑
fied by folate status among controls. We pro‑
pose that folate is permissive for an adaptive 
increase in DNA methylation and protective 
against hypomethylation of DNA that would 
otherwise increase risk for As‑induced health 
outcomes. The findings of the present study 
support this hypothesis because they indicate 
that hypomethylation of leukocyte DNA is 
associated with increased risk for skin lesions. 
Furthermore, these findings suggest that meth‑
ylation of PBL DNA may serve as a functional 
biomarker to identify individuals at risk for 
future skin lesion development. Large‑scale 
long‑term intervention studies will be required 
to determine if therapeutic strategies such as 
nutritional manipulation of one‑carbon metab‑
olism, which have the potential to increase As 
methylation and lower blood As, may lessen 
the burden of As‑induced skin lesions and 
other adverse health outcomes.
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